FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Aligos Therapeutics FCF Yield % Related Terms
Aligos Therapeutics FCF Yield % Historical Data
* Premium members only.
The historical data trend for Aligos Therapeutics's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:5WK0 vs SNTI, NTRB, CRVO: FCF Yield % Comparison
For the Biotechnology subindustry, Aligos Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aligos Therapeutics FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aligos Therapeutics's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Aligos Therapeutics's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aligos Therapeutics (STU:5WK0) has a FCF Yield % of -204.54 as of Jul. 09, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Aligos Therapeutics and its competitors. According to the industry distribution chart, Aligos Therapeutics ranks #1339 out of 1407 companies in the Biotechnology industry, placing it in the top 95.2%.
Is Aligos Therapeutics' FCF Yield % too high?
Aligos Therapeutics' current FCF Yield % is -204.54. Based on the distribution chart, Aligos Therapeutics ranks #1339 out of 1407 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Aligos Therapeutics has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aligos Therapeutics' FCF Yield % compare to SNTI and NTRB?
According to the Biotechnology industry distribution chart, Aligos Therapeutics ranks #1339 out of 1407 companies for FCF Yield %. This places Aligos Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Aligos Therapeutics and its competitors. Aligos Therapeutics's current FCF Yield % is -204.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aligos Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Aligos Therapeutics (STU:5WK0) is currently considered Significantly Overvalued. The stock's GF Value™ is €2.11, compared to a current price of €5.11 — trading 142.2% above its estimated fair value. The current FCF Yield % is -204.54. Aligos Therapeutics' overall GF Score™ is 25/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Aligos Therapeutics (STU:5WK0), the current FCF Yield % is -204.54 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aligos Therapeutics (STU:5WK0) Overvalued in 2026?
Based on GuruFocus' analysis, Aligos Therapeutics stock appears to be overvalued.
The current stock price of €5.11 is trading 142.2% above its estimated GF Value™ of €2.11.
GuruFocus considers Aligos Therapeutics to be Significantly Overvalued.
Key valuation signals for STU:5WK0:
FCF Yield %: -204.54
GF Value™: €2.11 vs. price of €5.11 (142.2% above fair value)
No single metric tells the full story. See the STU:5WK0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
25GF Score
Get the complete analysis for STU:5WK0
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:5WK0 has been successfully added to your 
